CompoundBrief

Research literature

Tesamorelin Trial Results Explained: What the Phase 3 and Liver-Fat Data Show

Published October 18, 2026 · 6 min read

Scope: Tesamorelin is an FDA-approved prescription drug with one labeled use, described below. This article walks through what the published trials and the FDA label report so you can read the numbers critically. It is not medical advice, not a dosing or use guide, and nothing here describes how anyone should use any compound. Compound Brief is published by DAAVY Research, which supplies laboratory research materials; a related disclosure appears near the end.

Tesamorelin gets talked about online as if it were a general-purpose “fat loss peptide.” The actual evidence is much narrower, and more interesting for it. Here is what was tested, in whom, and what came out.

The short version

Tesamorelin is approved in the United States for one thing: reducing excess belly fat in adults with HIV-associated lipodystrophy. Two large placebo-controlled trials found that deep abdominal (visceral) fat, measured by CT, dropped more on tesamorelin than on placebo. A smaller trial suggested liver fat might drop too. The FDA label is blunt about what it does not do: it is not a weight-loss drug, because body weight stays about the same. And every result below comes from people with HIV, so none of it tells us what would happen in anyone else.

What is tesamorelin?

It is a synthetic version of growth hormone–releasing hormone. Instead of supplying growth hormone directly, it nudges the pituitary gland to release more of the body’s own. The trials tracked this through IGF-1, a hormone that growth hormone drives upward.

The FDA label puts the approved use in one sentence: “indicated for the reduction of excess abdominal fat in HIV-infected adult patients with lipodystrophy.” Right after, it adds that the drug “is not indicated for weight loss management as it has a weight neutral effect.” The label cited here was most recently revised in March 2025.

What did the two big trials find?

The label describes two multicenter, randomized, double-blind, placebo-controlled studies: 412 patients in Study 1 and 404 in Study 2. Each had a 26-week main phase and a 26-week extension, with a daily injection of tesamorelin or placebo. The first was published in the New England Journal of Medicine in 2007 (Falutz and colleagues). The confirmatory trial was presented at the International AIDS Conference in Mexico City in 2008.

The main question was how much visceral fat (VAT) changed by week 26. From the label:

TrialTesamorelinPlaceboDifference (95% CI)
Study 1 (n=412)−18%+2%−20% (−24 to −15)
Study 2 (n=404)−14%−2%−12% (−16 to −7)

In absolute terms, that is a treatment difference of −31 cm² in Study 1 and −21 cm² in Study 2, measured on a CT slice. One practical warning: papers and the label can report slightly different percentages for the same trial, because analysis choices differ, such as how missing data are handled. Pick one source per comparison and stay with it.

In the extension, people who stayed on tesamorelin were compared with people switched to placebo. By week 52 the label shows treatment differences of −22 cm² (Study 1) and −35 cm² (Study 2).

What about liver fat?

This is where much of the recent interest comes from. A smaller trial at Massachusetts General Hospital (Stanley and colleagues, JAMA, 2014) asked whether tesamorelin also reduces liver fat in HIV-infected adults on antiretroviral therapy. Fifty people were randomized (28 to tesamorelin, 22 to placebo) for six months.

Visceral fat fell by 34 cm² on tesamorelin and rose by 8 cm² on placebo, a treatment effect of −42 cm² (95% CI −71 to −14). Liver fat, measured as a percentage, changed by a median of −2.0% on tesamorelin versus +0.9% on placebo.

Before getting excited, note how the authors framed it. They called it a preliminary study. Drug supply problems stopped recruitment early, so only 43 people finished, and the study was built around visceral fat, not liver fat. Their own conclusion: “further studies are needed to determine the clinical importance and long-term consequences of these findings.”

What side effects were reported?

The label lists adverse reactions that were at least 1% and more common on tesamorelin than placebo during the 26-week phase (placebo n=263, tesamorelin n=543). The biggest gaps:

ReactionPlaceboTesamorelin
Injection site reaction6%17%
Arthralgia (joint pain)11%13%
Myalgia (muscle pain)2%6%
Peripheral edema2%6%
Paresthesia2%5%

The warnings go further: a possible increased risk of neoplasms, elevated IGF-1, fluid retention, glucose intolerance or diabetes, hypersensitivity reactions (4% of treated patients), and increased mortality in acute critical illness. The label lists four contraindications: active malignancy, disruption of the hypothalamic–pituitary axis, known hypersensitivity, and pregnancy. In the liver-fat trial, fasting glucose rose slightly at two weeks on tesamorelin (treatment effect 7 mg/dL), but the difference at six months was not significant.

What the evidence doesn’t tell us

The takeaway

Tesamorelin is a useful example of how to read drug evidence. It has a clear approved purpose, a measured effect on one imaging outcome, and a published safety profile. That is a long way from the sweeping claims you see in forums and product listings. When you meet any compound summary, ask two questions: who was studied, and was the thing measured the thing people actually care about? For help with trial tables and confidence intervals, see How to Read a Clinical Trial Result.

Disclosure: DAAVY Research, which publishes Compound Brief, lists a tesamorelin 10 mg research material for laboratory use only. It is not the approved drug product, is not intended for human or veterinary use, and nothing in the trials above applies to it. Its third-party lab report is COA9237.

Sources

← Back to all articles